It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Delivering custom, physiologically relevant GABAA assays that move programs forward faster. From high-throughput screening to native human models, we combine deep pharmacology expertise with flexible assay design to generate robust, interpretable data.
Access a comprehensive GABAA portfolio designed for flexibility and precision. Formats, readouts, and workflows are tailored to your mechanistic or translational goals helping you answer critical questions with actionable data.
Our subtype panel supports selective compound characterization with subtype resolved pharmacology. Using automated electrophysiology and fluorescence -based screening in 384 and 1536 well formats, this platform enables both high throughput screening and detailed mechanistic studies that reveal subtle differences in efficacy and selectivity.
GABAA Subtypes
α1β1γ2
α4β1γ2
α1β2γ2
α4β2γ2
α1β3γ2
α4β3γ2
α2β1γ2
α5β1γ2
α2β2γ2
α5β2γ2
α2β3γ2
α5β3γ2
α3β1γ2
α6β1γ2
α3β2γ2
α6β2γ2
α3β3γ2
α6β3γ2
α4β3δ
α6β3δ
High-Quality GABAA Assays
Automated and manual electrophysiology platforms deliver reproducible data across an extensive GABA A receptor subtype panel. Rigorous quality control ensures signal stability and consistency for confident decisions.
High quality electrophysiology data
Excellent reproducibility
Flexible plate layouts
Rapid turnaround times
Functional Selectivity and Hit Identification
High -throughput screening across our full GABAA receptor subtype panel identifies hits efficiently while revealing distinct pharmacology profiles. Subtype-resolved data differentiates on-target activity from off-target effects, guiding lead prioritization and efficacy optimization.
Early CNS Safety Profiling
Early -stage CNS safety evaluation includes profiling against key GABA A subtypes to flag off -target pharmacology. By quantifying agonist, inverse agonist and modulatory effects with precision, ourn assays help de -risk compounds before clinical development.
iPSC-Derived Sensory Neurons
Our RealDRGxTM iPSC -derived sensory neuron assays provide a native human context for translational electrophysiology.
Assay Reproducibility and Stability
High-quality electrophysiology data ensures consistent, reproducible assay performance for confident screening decision.
Translational Relevance of iPSC-Derived Sensory Neurons To address the critical need for scalable and human-relevant…
Case Studies
Related Capabilities
We bring together a dynamic blend of new talent and experiences pharmaceutical industry experts from around the world, delivering excellence across each stage of discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Precise ion channel and transporter insights through tailored electrophysiology studies supporting target validation, hit identification, and lead optimization decisions.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
